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Abstract
In October 2015 the UK enacted legislation to permit the clinical use of two cutting
edge germline-altering, IVF-based embryonic techniques: pronuclear transfer and
maternal spindle transfer (PNT and MST). The aim is to use these techniques to
prevent the maternal transmission of serious mitochondrial diseases. Major claims
have been made about the quality of the debates that preceded this legislation and
the significance of those debates for UK decision-making on other biotechnologies,
as well as for other countries considering similar legislation. In this article we
conduct a systematic analysis of those UK debates and suggest that claims about
their quality are over-stated. We identify, and analyse in detail, ten areas where
greater clarity, depth and nuance would have produced sharper understandings
of the contributions, limitations and wider social impacts of these mitochondrial
interventions. We explore the implications of these additional considerations for
(i) the protection of all parties involved, should the techniques transfer to clinical
applications; (ii) the legitimacy of focussing on short-term gains for individuals
over public health considerations, and (iii) the maintenance and improvement
of public trust in medical biotechnologies. We conclude that a more measured
evaluation of the content and quality of the UK debates is important and timely:
such a critique provides a clearer understanding of the possible, but specific,
contributions of these interventions, both in the UK and elsewhere; also, these
additional insights can now inform the emerging processes of implementation,
regulation and practice of mitochondrial interventions.
Keywords: Mitochondrial diseases, Three-genome embryo, UK regulation, UK
debates, PNT/MST, Mitochondrial donation
Introduction
In October 2015 the UK became the first country to enact legislation, originally agreed
by Parliament in February 2015, to permit the clinical use of embryos that have been
constructed using genetic material from three people. The purpose of constructing
such embryos is to allow women who carry certain types of incurable mitochondrial
disease to attempt to have genetically related children who will, it is hoped, be free
from such diseases. Following a decade of research, two IVF-based techniques have
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been developed: (i) pronuclear transfer (PNT) and (ii) maternal spindle transfer (MST),
both often erroneously referred to as ‘mitochondrial donation’ (Haimes and Taylor
2015).1 In both techniques the intending parents’ DNA is transferred into an egg
(containing healthy mitochondria) provided by another woman, from which the nuclear
DNA has been removed. Both techniques therefore result in a ‘constructed’ embryo
that contains DNA from three people: nuclear DNA from the intending mother, nu-
clear DNA from the intending father and mitochondrial DNA from the woman acting
as the egg provider. Elsewhere we have described the resulting embryo as a ‘three-
genome embryo’ in a challenge to the more commonly used phrase of ‘three parent
babies’ (Haimes and Taylor 2015).
Major claims have been made about the quality of the UK debates leading up to
the February 2015 decision and the significance of those debates for UK decision
making on other biotechnologies, and for other countries considering whether to
approve mitochondrial therapies. For example, the UK’s Government Chief Scien-
tific Adviser, Sir Mark Walport, asserted that ‘approval in the United Kingdom of
mitochondrial donation provides a blueprint for future decisions on modifying the
genome’ (Hawkes 2015). In December 2015 Walport also said of the UK, ‘…we are
good at the science, we’re very good at the regulation and we’re very good at the
public discussion.’ (Knapton 2015).
However, in this article we suggest that these claims about the quality of the UK
debates around mitochondrial interventions are somewhat over-stated. Through a sys-
tematic analysis of the published documents and statements that were produced by key
participants in those debates we identify ten areas where greater clarity, depth and
nuance would have produced a more rounded debate over the field of mitochondrial
interventions. We suggest that a more careful consideration of these areas sharpens un-
derstandings of the contributions, and limitations, of mitochondrial interventions as
well as of their wider socio-ethical impacts. Our analysis of the ways in which wider de-
bates over mitochondrial interventions could be improved is very timely. In December
2016 the UK regulatory agency, the Human Fertilisation and Embryology Authority
(HFEA) will decide whether to issue licences to clinics to allow them to pursue these
clinical applications; also, other countries, such as the USA, are considering whether to
approve such interventions. Our review of, and suggestions for improving, the UK
deliberations, contribute to discussions over mitochondrial interventions in other juris-
dictions; it also contributes to a growing literature on innovations and governance in
biotechnologies more generally.
Background
Mitochondrial interventions, hereafter referred to as PNT/MST to better reflect the actual
techniques under scrutiny, have provoked much discussion because they involve changing
the genetic inheritance of any children born, in novel, untried, irreversible ways that could
never occur through ‘natural’ conception. Further, this genetic change will be perpetuated
in future generations who are descended from any girls born using this approach, because
it is a form of germline modification. As noted above, the use of these techniques is justi-
fied by the aim to prevent the maternal transmission of some types of mitochondrial
disease. It is therefore pertinent to provide some contextualising information (see also
Bredenoord and Braude 2011).
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Mitochondria and mitochondrial diseases
Mitochondria are small structures (organelles), multiple copies of which are found in
almost all human cells,2 including gametes; they are the sites at which the energy that
sustains life is produced. Uniquely amongst organelles, mitochondria possess their own
DNA (mt-DNA) which is distinct from the nuclear DNA that contains the majority of
a person’s genetic material. The mitochondrial genome is composed of 37 genes, 13 of
which code for proteins involved in energy production. It is estimated that there are
around 21,000 genes in the nuclear DNA (Pennisi 2012).
Mitochondrial diseases, which result from a reduction in the capability of mitochon-
dria to produce energy, are complex. There are many different mitochondrial diseases,
which range in severity and age of onset, some of which are difficult to diagnose. Both
sexes can suffer from mitochondrial diseases and the same disease can affect different
individuals to varying degrees. Some mitochondrial diseases are caused by mutations in
the mt-DNA, though not every mitochondrion may carry the pathogenic mutation; it is
this variation in ‘mutation load’ that accounts for the variability in the way the mito-
chondrial diseases affect different individuals.
Inheritance
Mitochondrial-DNA is inherited only through the female line, as all the mitochondria
in a developing embryo are derived from those originally present in the egg. Complex
and incompletely understood patterns of replication of mitochondria in the developing
embryo mean that it is rarely possible to predict accurately the severity of mito-
chondrial diseases. Nonetheless, if a woman has a disease-causing mt-DNA muta-
tion, she will inevitably pass that mutation on to all her children. It is maternally
transmitted mt-DNA disease, as opposed to mitochondria diseases from de novo
mutations, that clinician-scientists3 hope to eradicate from families through the use
of PNT/MST.
Regulation
All research and treatment in the UK that uses gametes and embryos is regulated by the
Human Fertilisation and Embryology Authority (HFEA), the body established by the
Human Fertilisation and Embryology (HFE) Act (1990). The original HFE Act has been
amended on several occasions to take account of developments in science; each amend-
ment requires debate and a majority vote in Parliament to be enacted. In 2001 an amend-
ment was made to permit the HFEA to license research that would increase ‘knowledge
about serious diseases’ and to enable ‘any such knowledge to be applied in developing
treatments for serious disease’ (HM Government 2001). In 2005 it was argued that mito-
chondrial diseases were ‘serious’ and the HFEA granted a research licence to clinician-
scientists at Newcastle University4 to permit them to conduct research on PNT/MST,
though at that point it remained illegal to use an embryo created by the techniques for
clinical applications. Then in 2008 the HFE Act was amended,
… introducing new powers which allow for Regulations to be passed by Parliament
that will allow techniques that alter the DNA of an egg or embryo to be used in
assisted conception, to prevent the transmission of serious mitochondrial disease
(HFEA 2013, 9).
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In May 2010 the HFEA reviewed developments in the science and, in collaboration
with the Newcastle clinician-scientists, made a request to the Government to invoke
the provision for such Regulations to be debated. This led to debates in Parliament and
the subsequent change in the law, in February 2015. This change was then enacted on
October 29th 2015.
Sharpening the UK debates on the clinical applications of PNT and MST
In analysing the UK debates we conducted a systematic review of the major regulatory,
scientific, clinical and bioethics contributions in the public domain that preceded the
February 2015 decision. These included: (i) all Parliamentary debates from both the
House of Commons and the House of Lords; (ii) all reports from the HFEA relating to
mitochondrial interventions, including its public consultation on this subject; (iii) major
bioethics commentaries, including the 2012 report from the Nuffield Council on Bio-
ethics on ‘Novel techniques for the prevention of mitochondrial DNA disorders: an
ethical review’, and (iv) contributions from patient groups. We also reviewed how these
discussions were represented in the mass media and have used elements of these to il-
lustrate how arguments made in one sector became translated across to other sectors
(for example, from the scientific to the mass media to the Parliamentary debates: see
section (v) below5). An analysis of these debates reveals a number of areas that were
neglected or marginalised or that lacked depth and nuance in certain key aspects des-
pite being crucial to the development and implementation of these techniques. We
have identified ten areas that would benefit from greater consideration and suggest
ways in which that further scrutiny might develop. We then discuss the implications of
these issues for ongoing debate on treatments for mitochondrial diseases and for the
governance of other biotechnologies in the near future, in the UK.
(i) Other ways to have a baby.
One of the most prominent gaps in the UK debates of mitochondrial interventions was
the absence of consideration of other reproductive possibilities available to affected
women, accompanied by a failure to weigh, systematically, the costs and benefits of each
option against the others. Instead the new science of mitochondrial intervention was the
starting point for deliberation and was presented in some quarters as the only desirable
way in which women with faulty mitochondria could have healthy babies. The alternatives
of ‘traditional’ full egg donation,6 surrogacy with egg donation, or adoption, were rarely
discussed, let alone given detailed or informed consideration. For example, even an organ-
isation as well versed in assisted conception as the HFEA made no reference, in its advice
to Government resulting from its public consultation, to these other ways that affected
women could have a healthy child. This suggests that these alternatives were not
prominent in their deliberations or in the consultation processes (HFEA 2013).
Similarly, Chinnery et al. (2014) state,
Mitochondrial DNA diseases are transmitted maternally, and for families carrying
these mutations, a major, and justifiable, desire is to have unaffected children. For
some women, pre-implantation or prenatal diagnosis may be helpful [4,5], but for
other women, these techniques will not result in disease free offspring and the only
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options available are either oocyte donation or mitochondrial replacement at the oo-
cyte or zygote stage. The need for this technique for these families is well established,
as are the experimental methods that are required for mitochondrial replacement
[6–8] (2014, 1, emphasis added).
In claiming that the ‘need’ for mitochondrial interventions is ‘well-established’, Chinnery
et al. (2014) provide no evidence from affected women or families7 themselves.
However, Herbrand (2016) suggests that such women face much more complex re-
productive choices and do not regard PNT or MST as the simple solutions that
they were presented as being.8
(ii)Valorising ‘genetic connections’.
The difference between the above-mentioned alternatives and PNT/MST is that, with
the latter, the person conceived would be genetically related to the intending parents. The
observation that PNT/MST provided the only route through which an affected woman
could have genetically related children was the explicit starting point for the Parliamen-
tary debates in 2015. The House of Commons debate opened with the statement,
Ellison: … The techniques provided for by these regulations offer the only hope for
some women who carry the disease to have healthy, genetically related children who
will not suffer from the devastating and often fatal consequences of serious
mitochondrial disease (Hansard, 2015a: Col 160).
Similarly in the House of Lords, The Parliamentary Under-Secretary of State at the
Department of Health opened the debate saying,
My Lords, the purpose of the regulations is to enable women to have their own
genetic children, free of terrible disease caused by disorders in their mitochondrial
DNA (Hansard, 2015b: Col 1569).
Such opening statements set the terms for these debates and thereby limited the
opportunity to debate alternative approaches, by establishing the view that genetic
relatedness was a key consideration driving the development of the techniques.
Sometimes the centrality of concerns around genetic relatedness was simply assumed,
particularly in the media coverage where this was often coupled with another trope in
these discussions, a reference to the plight of named individuals and families. McKie,
for example, noted in The Observer newspaper, that one woman whose son died of a
mitochondrial disease has a surviving daughter and wants,
this new technique to be given the go-ahead, so my daughter will have healthy mito-
chondria and can have children who will not die when they are teenagers, as her
brother Adam did (2014, 19).
A Daily Mail article reported that ‘Women carrying damaged mitochondria can also
miscarry repeatedly and often face the heartbreaking choice of whether it would be best
to remain childless’ (Macrae 2014). Neither of these pieces (typical of the many
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published) mention the alternative routes that affected women could take to become
mothers of healthy children, again reinforcing the assumed importance of the genetic
connection sustained by PNT/MST. The Macrae article also raised the notion of
‘choice’ which was common in many contributions to these discussions. When ques-
tioned on the possibility of using non-PNT/MST methods to conceive, an affected
woman interviewed on a BBC national news programme on the day of the House of
Commons debate, said that the mitochondrial techniques would give her, and women
like her, ‘choice’. She did not expand on that though the insinuation within the context
of the discussion was that this is the choice to have a genetically related baby; this was
not pursued by the interviewer, as if ‘choice’ in and of itself was an unquestioned value.
Whiteman (2013) argues,
‘Choice’ is a word that has, arguably, become near-ubiquitous in UK political dis-
course. It has an air of simplicity in meaning, ingrained in casual use and yet the
word is value-ridden. The term ‘choice’ in the context of health care and beyond has
become an extension of expressing (or choosing) preferences. To have choice implies
that there is the opportunity for an individual to have what they want, when they
want it; demand if you will (2013, 148).
This emergence of the language of choice and consumerism in the discourse around
health care provision in the early 2000s coincided with the long period of development
of PNT/MST (Fotaki, 2010, 898). Nonetheless, in the context of the radio interview
and other discussions around mitochondrial interventions, the notion of ‘choice’ was
used to close down consideration of existing alternatives and to promote the new inter-
ventions, by those who were advocates for the science and by those who prioritised
genetic relatedness between parents and children. Genuine discussion of choice in con-
ception and reproduction (and more generally) would clearly have been an important
aspect to add to these debates, given that families in twenty-first century UK are com-
posed of individuals with a diverse range of genetic relationships, or none at all.
However, it is important to note that the valorisation of ‘choice’ and ‘genetic connec-
tions’ in this context was heavily skewed towards the assumed interests of the intending
parents. Any ‘child’ resulting from these interventions will not be allowed access to
identifying information about the woman who provided the egg and who therefore
made that child’s existence possible. A person conceived through PNT/MST will be
able to apply for information to confirm that s/he is the result of ‘mitochondrial donation’
and also be given information about the egg provider’s personal and family medical his-
tory, the screening she underwent prior to egg provision, and any other information
lodged by the egg provider. However, the person conceived cannot be given ‘any informa-
tion which may identify the mitochondrial donor’ (HM Government 2015). The absence
of discussion about the longer-term interests of the person conceived is perhaps attribut-
able to the fact that s/he was generally referred to, and portrayed in all the discussions, as
either ‘a baby’ or ‘a child’, with little or no acknowledgement of the fact that s/he will
become a fully independent adult with his/her own views about the importance, or other-
wise, of ‘choice’ or ‘genetic connections’9 (Haimes 1998). Crouch (2016) has similarly
commented that the UK discussions tended to focus on the needs of the intending
parents rather than those of the person conceived, either as a child or in the longer term.
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(iii)Safety issues.
As fundamental as the question, ‘what alternatives are available?’ is the question, ‘how
safe is the proposed new intervention?’ Questions of the safety of PNT/MST were
addressed by a Safety Review Panel (hereafter, the Panel) convened by the HFEA, to
‘review the latest evidence of safety and efficacy’ (HFEA 2014, 9).
The Panel’s third report comments,
From a medical or scientific point of view all novel treatments pose essentially the
same question: when is a treatment safe to offer? Research can never answer every
question before a new treatment is offered, nor can it be expected to guarantee safety
or efficacy when applied for the first time in the clinic. It can only serve to reduce the
risk and to highlight areas that need close attention. … the panel concluded both in
2011 and 2013 that the evidence available at those times did not suggest that the
techniques are unsafe. The direction of travel remains the same, and the panel
therefore come to the same conclusion in this report (HFEA 2014, 5, emphasis added).
Clearly the argument that it cannot be fully known whether new treatments are safe
until they are tried in human beings is correct but it is questionable whether the appro-
priate comparator was addressed by the Panel. Medicines or medical devices that do
not behave as safely as expected might well affect the first individuals to receive them,
but PNT/MST are interventions of a different order, with the potential to affect the
whole human species, rather than a series of individuals, because they change the
germline. Given that there are existing alternative ways for affected women to try to
conceive, it can be argued that a stronger indication of safety should have been re-
quired for the introduction of the new techniques.
This suggestion is supported by the number of scientists who questioned claims
about the safety of PNT/MST during the period of the UK debates. Ishii (2014) raised
concerns about: (i) the lack of specific knowledge of the link between particular genetic
mutations and ‘dysfunction at cellular organ and systematic levels’ (2014, 153); (ii) the
potential for problems to arise from mt-DNA and nuclear DNA interactions, and (iii)
the unknown effects on epigenetic programming during development of any embryo
resulting from PNT/MST. Ishii was also concerned that other countries might follow
the UK lead before the safety questions had been adequately addressed. The stem cell
scientist Paul Knoepfler (2014) raised similar concerns and additionally identified the
potential for ‘preferential replication’ of any damaged mitochondria carried over to the
constructed embryo from the affected woman’s egg; this would result in increasing
numbers of damaged mitochondria in the developing embryo at the cost of healthy
mitochondria, so the person conceived would still inherit the mother’s pathogenic
mitochondrial DNA. Morrow (2014) raised concerns about potential problems from
mismatching nuclear and mitochondrial DNA and also pointed out that it is,
a contradiction to claim [as some proponents do: see section (vi) below] that
mtDNA is not important for an individual's characteristics … while at the same
time acknowledging that changes in the mitochondrial genetic code are important for
an individual's risk of disease (2014).
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St John (2014) identified the need to avoid any transfer of damaged mitochondria from
the affected woman’s egg, and the practical difficulty of doing so, describing animal exper-
iments that have shown the persistence of damaged mitochondria. He also raised con-
cerns about epigenetic effects and mismatching of nuclear and mitochondrial DNA.
A prominent theme in discussions about safety was whether it is possible to separate
‘safety’ issues from ‘ethical’ issues. The Panel set explicit boundaries around their con-
tribution to the debates by saying, ‘this review focuses exclusively on the science and
the safety and effectiveness of these techniques; it does not consider the ethical and
legal issues that are raised by such techniques…’ (HFEA 2014, p9). Similarly, Walport
was reported to say:
People have extreme beliefs about whether it is right for humans to tamper with
embryos in any way at all. Sometimes the values discussion gets conflated with the
science discussion. We shouldn't pretend we're having an argument about science
when we're having an argument about values. People need to say [why] they really
object and not duck why they object by pretending there is something wrong with
the science (Knapton 2015).
Nonetheless, some Parliamentarians echoed the above safety concerns while making
clear that they had principled, ethical, objections, distinct from, but additional to, concerns
about safety. For example, Bruce stated,
I want to speak against the Government motion… Human mitochondrial disease is a
dreadful condition and, as a caring society, we must do all we can to address it… in
an ethical manner and with proper regard for safety. I believe that the regulations we
are considering today fail on both counts—ethics and safety—and that they are
inextricably interlinked. Let me be straightforward: I do oppose these proposals in
principle. However, that should not prevent my concerns regarding their safety from
being given a fair hearing (Hansard 2015a: col 168).
Equally, neatly separating safety from ethical issues was not easy for the participants
in the HFEA consultation:
The public dialogue and consultation work we undertook was focused on gathering
and understanding public views on the social and ethical issues associated with
mitochondria replacement. We wanted to explore their views independent of any
questions of safety and efficacy. In practice, however, people’s views on these issues
tended to be linked to questions of safety; this was a strong theme through all the
responses. Sometimes, safety concerns become a proxy for concerns about ethical
and social issues, which are often hard to express. On other occasions, support
for mitochondria replacement dipped when the scientific evidence was less clear
(HFEA 2013, para 6.8, emphasis added).
Clearly, issues about the safety of any intervention cannot be neatly distinguished
from socio-ethical concerns, not least because it can never be morally correct to offer
interventions that are known to be unsafe, except under exceptional circumstances and
where no alternatives exist. On the more general point, there is also not as clear a
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divide between science and values as some contributors suggested: as we have seen
above, PNT/MST are partly being offered in the first place because of the largely
unstated valorisation in the scientific literature of genetic ties between parents and chil-
dren. The vast literature from Science and Technology Studies identifies the numerous
ways in which ‘science’, far from being an external source of objective knowledge,
is inextricably shaped by, and shapes, wider social values, institutions and processes
(e.g. Jasanoff 2004).
It is worth noting that papers published since the 2015 UK legislation indicate that
earlier concerns about the safety of PNT/MST are justified. Callaway (2016) reports that
work carried out by Egli’s group in New York (Yamada et al. 2016) found, as Knoepfler
feared, that small amounts of the intending mother’s damaged mt-DNA might be carried
over and ‘outcompete healthy mitochondria in a child’s cells and potentially cause the
disease [that] the therapy was designed to avoid’. Further evidence of this phenomenon
was reported in Nature in November 2016 (Kang et al. 2016; Cook 2016b). Egli argued
that this problem would ‘defeat the purpose of doing mitochondrial replacement’ and
recommended that the procedure not be used in the meantime, arguing ‘I don’t think it
would be a wise decision to go forward with this uncertainty’ (quoted in Callaway, 2016).
This was followed by a letter to Nature from the Newcastle team reporting the first
pre-clinical studies on PNT and acknowledging the importance of reducing mt-DNA
carry over. The authors concluded that ‘PNT has the potential to reduce the risk of
mtDNA diseases, but it may not guarantee prevention’ (Hyslop et al. 2016, 2) and that
therefore ‘it should be considered in combination with prenatal screening’ (2016, 4).
The lead Newcastle scientist, Professor Sir Doug Turnbull, was reported by the BBC as
saying their letter sounded ‘a note of caution’. Surprisingly, however, the BBC headlined
their article with the words: ‘Three-person babies IVF technique “safe”’ (BBC 2016).
The Times newspaper assumed a smooth and unruffled progression to successful im-
plementation, headlining a piece that reported the Newcastle letter with the words:
‘Three-parent babies could be born next year if new IVF wins approval’ (Moody, 2016).
Rather more cautiously Knoepfler was quoted as saying that both the Yamada paper
and the Newcastle letter ‘clearly indicate that the field is not ready to use this technology
to create actual people. It would be reckless to do so… To their credit the [Newcastle]
group acknowledges this challenge…’. Knoepfler goes on to say that ‘the legislative ap-
proval of this technology for use in humans in the UK last year, based in part on vigorous
claims from proponents in the UK that there were plenty of data already, was more
political than scientific.’ (Cook 2016a).
(iv)The focus on children and severe forms of disease.
A facet of the discussion that made such a political decision possible was the
clear focus on babies and children, and on the most severe forms of mitochondrial
diseases, by the mass media and patient advocacy groups. This is rather misleading
since many mitochondrial diseases only manifest themselves in adults and have
varying degrees of severity (NCoB 2012, Dimond 2015). It would have been more
transparent (and the calculations of the numbers of affected persons would be
higher) if the case in favour of allowing these techniques had reflected the full
range of affected persons.
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It could be argued that the devastating conditions that affect babies and young chil-
dren are predominantly the conditions that the proposed techniques will be used to
prevent. However, the women who are the targeted beneficiaries of PNT/MST have
mitochondrial disease themselves and yet have a quality of life that has enabled them
to get to the point of wanting to start a family; this is an indication that the impact of
mitochondrial diseases is much more variable than presented in the debates. Therefore
the focus on babies and children was a missed opportunity to raise awareness of the
full range of mitochondrial diseases, and their manifestations, and of the differing
experiences of living with such conditions.
However, that focus also had the effect of suggesting that affected babies would be
the beneficiaries of the proposed intervention, which is clearly not the case. A healthy
child might be the result of the intervention, but children affected by mitochondrial
disease are not the site of the proposed intervention.
(v)The potential for raising unrealistic expectations.
As we have said, not all forms of mitochondrial disease are caused by mutations in
the mt-DNA, but it is only disease caused by such mutations that the clinician-
scientists hope to tackle using PNT/MST. When developments on PNT/MST were
reported in the media, however, the complexities and nuances of the nature of
mitochondrial diseases were often lost, leaving readers with the impression that ‘mito-
chondrial diseases’ can be ‘prevented’ or ‘eliminated’. For example, Collins (2012) in the
Daily Telegraph quoted Professor Turnbull as listing specific examples of mitochon-
drial disease, including muscular dystrophy and ataxia and stating that the hope for
PNT/MST was to ‘totally prevent the transmission of these diseases’ (Collins 2012).
The journalist, however, then went on to cite the number of children (around 200) esti-
mated to be born each year with any form of mitochondrial disease and did not clarify
that only a smaller proportion of these had the conditions Turnbull described. Another
example was a Guardian piece by their science editor, Ian Sample. Titled ‘”Three-parent
babies” cure for illness raises ethical fear’, the article was not primarily concerned with
ethical fears, but rather was a wide-ranging description of the potential of the work
being done on PNT/MST. The article showed the same potential for confusing readers
by referring to ‘mitochondrial disease’ as if this only arises from mt-DNA mutation,
and gave the impression that all women affected by ‘mitochondrial disease’ would bene-
fit from the new interventions. Sample also wrote that,
In Newcastle, Turnbull is working on ways to eliminate the risk of disease by replacing
the mother's faulty mitochondria wholesale with those from a healthy donor (2012).
Again, this does not reflect the complexity of the situation, a position that was
exacerbated when he quoted the leading American clinician-scientist working on MST,
Mitalipov says funding restrictions mean he cannot take the research on in humans.
“We hope the UK takes it further. We have a way to prevent transmission of these
diseases in children. It has to be tested or we will never know if it works,” he says
(Sample 2012).
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The lack of clarity about the range of conditions that will be valid targets for attempts
to prevent transmission from mother to child is evident; the overall impression is that
all mitochondrial diseases will be prevented.
Such lack of clarity might be dismissed as merely typical of journalistic oversimplifi-
cation, were it not for the observation that some policymakers appeared to be suscep-
tible to the misconceptions that can arise from these stories. The Member of
Parliament Luciana Berger began her contribution to the House of Commons debate
on legalising PNT/MST for clinical use by noting that she had followed the ‘public
debate’ for ‘recent weeks and months’, and attended a Parliamentary event where ‘we
heard representations from both sides’. She reached the conclusion that,
We have within our reach the possibility of eradicating mitochondrial disease
from families who have been blighted by it for generations: families who have
endured a disease for which there is no cure, who have suffered daily battles with
painfully debilitating symptoms, and who have sadly lost their children prematurely
(Hansard 2015a: Column 164).
However, as Herbrand (2016) highlighted, a later exchange in the debate revealed a
fundamental misunderstanding,
Gillan: Can [you] confirm that mitochondrial disease from the nuclear DNA will
remain in our population even after this treatment is licenced?
Berger: […] it is not something I have been made aware of, and it certainly has not
come up in any of the discussions or debates that I have attended (Hansard 2015a:
Column 168).
The conflation of ‘mitochondrial disease’ with specific serious mitochondrial diseases
caused by mt-DNA mutations, plus the lack of clarity that ensues from the conflation of
‘preventing transmission’ with the numbers of children estimated to be affected by all mito-
chondrial diseases, results in the inflation of hope and expectation for the proposed inter-
ventions; not least expectations about the public health impact of permitting PNT/MST.
This sort of discourse in the UK debates meant that PNT/MST were not systematic-
ally evaluated against other necessary interventions for the wider range of mitochon-
drial diseases; it also meant that the possibility of new mt-DNA mutations resulting in
mitochondrial diseases featured little in these discussions.
(vi)The paradox of small numbers…or the insignificance of significant genes.
As noted above the human mitochondrial genome is very small in comparison to
the total size of the human genome. This fact was deployed in interesting ways by
some proponents of PNT/MST. For example, the UK’s Chief Medical Officer,
Dame Sally Davies, said:
It is important to remember that mitochondrial DNA represents less than 0.054% of
the total DNA, and is not part of the nuclear DNA, which determines our personal
characteristics and traits such as personality, hair and eye colour. (Davies 2015).
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Similarly, a campaigning patient group, the Lily Foundation, which provides help and
advice for parents with children who have mitochondrial disease, explained in some
web-based information:
The baby would have <0.1% of their total DNA from a 3rd person and this would be
the mitochondrial DNA (mtDNA) in the donated mitochondria which enables
normal energy production.
The overwhelming majority of the DNA, 99.9% (all the nuclear DNA that
determines human characteristics) would only come from the mother and father
(Lily Foundation 2015).
Parliamentarians echoed these statements; for example in the House of Commons
debate on February 3rd, 2015,
McInnes (Heywood and Middleton) (Lab): As we have heard, mitochondrial DNA
makes up a tiny proportion of our total DNA. … There are 37 genes in mitochondrial
DNA, which is less than 0.01% 10 of our total DNA (Hansard 2015a: Col 179).
The Parliamentary Under-Secretary of State for the Department of Health, when
opening the Lords debate, said ‘the DNA from the donor egg amounts to less than 1%
of the resulting embryo’s genes’ and that ‘One important point to emphasise here is
that none of the nuclear DNA, which determines our personal characteristics and
traits, is altered by mitochondrial donation.’ (Hansard 2015b: Col 1569). Other exam-
ples abound. This is not the place to enter into argument with the claim that nuclear
DNA ‘determines’ personality, other than to note that the presence or absence of mito-
chondrial disease is likely to have a profound impact on an individual’s personality
(NCoB 2012; Baylis 2013; Haimes and Taylor 2015). More important to note for our
analysis here is the way in which claims about the tiny portions of donated mt-DNA
are configured. The implication of this repeated refrain is that, because the numbers
being discussed are so small, the genetic material to which they refer is unimportant
and insufficient to provoke concern. And yet, without these tiny amounts of mt-DNA,
an affected woman would have no hope of bearing a healthy, genetically-related child –
which of course is the whole point of these discussions in the first place. Minimising
the contribution of the mitochondrial genome in numerical terms means that the pro-
ponents of the techniques were making paradoxical claims: saying these interventions
and therefore these genes are both crucial (to prevent transmission of mitochondrial
diseases) but are also essentially insignificant because they are only few in number. The
insinuation is that opposing an intervention which involves such a small amount of
genetic material could be nothing but unreasonable.
A further effect of establishing the notion that the mitochondria from the
‘healthy egg donor’ are providing only a small number of genes, is that it dimin-
ishes the importance of, and indeed helps to render invisible, the women who pro-
vide those ‘healthy’ mitochondria, and the labour involved in providing them, as
we discuss in section (ix) below.
(vii)The number of affected individuals and families.
Haimes and Taylor Life Sciences, Society and Policy  (2017) 13:1 Page 12 of 25
Just as numerical calculations were deployed to minimise and deflect concerns about
the proposed interventions, they were also deployed to strengthen the case in favour of
these interventions, albeit in confusing and inconsistent ways.
In a letter to Nature in 2010, the Newcastle group reported that,
[m]utations in mitochondrial DNA (mtDNA) are a common cause of genetic
disease. Pathogenic mutations in mtDNA are detected in approximately 1 in 250
live births and at least 1 in 10,000 adults in the UK are affected by mtDNA disease
(Craven et al. 2010, 82).
Using publicly available information, we can use these figures to estimate that around
5280 adults in the UK are affected by mt-DNA diseases.11 However, until 2015, the
number of families to be treated through PNT/MST per year was often cited in debates
as ‘around 10’ (for example (BBC 2013), Sample (2013)) though it is unclear from
whence this figure originated. Just before the 2015 House of Commons debate, the
Newcastle Group estimated that the ‘average number of births per year among women
at risk for transmitting mtDNA disease’ was 152, from a population of 2473 affected
women in the UK suggesting that in the future about 150 births per year could poten-
tially benefit ‘if all women opted for the procedure’ (Gorman et al. 2015, 886-7). Again,
using publicly available figures and an alternative approach to estimating the number
of women who might be able to benefit from PNT/MST, it is possible to estimate that
the number of children born each year who may be affected by serious mitochondrial
disease is between 112 and 148.12 (See also Herbrand 2016).
Clearly the figures cited depend on the starting point for any particular calculation.
Some of the confusion in the early discussions about the numbers of women, babies and
families involved might have arisen from a lack of clarity about: (i) the number of women
carrying faulty mitochondria; (ii) the number of those who might seek to get pregnant
each year; (iii) the number of babies likely to be born from those women; (iv) the number
of people in families likely to be affected by the birth of a severely affected baby; (v) the
numbers of babies that could be conceived through natural pregnancy (and who would
therefore be highly likely to be affected); (vi) the number of babies that could be conceived
using IVF, knowing that IVF only has a success rate of about 30% (an often unacknow-
ledged aspect in the ‘public discussion’). It is important therefore that the basis of any cal-
culation is clearly established before making any claims or drawing any conclusions from
those figures. The Newcastle Group clarified many of these issues through analysis of
their patient registry and Office of National Statistics data (Gorman et al. 2015); it is to
their credit that they published these findings ahead of the Parliamentary debates.
(viii)Regulatory oversight and capacity.
This lack of consistency and clarity was significant for the UK debates in another
way. A requirement of the UK legislation was that the HFEA must review each applica-
tion to use PNT/MST in a woman’s treatment, on a case-by-case basis; this step was
consistently noted to be an important safeguard in the clinical application of these
techniques. For example, an HFEA press release, following the passage of the regula-
tions through Parliament, noted,
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Each application will be decided on a case by case basis and in accordance with the
latest scientific advice. An HFEA committee will determine whether individual
patients and families have a particular risk of an abnormality in their mitochondrial
DNA; and whether there is a significant risk that a child born with that abnormality
will have, or will develop, a serious physical or mental disability, a serious illness or
another serious medical condition (HFEA 2015).
While 10 cases per year might be manageable, the question of how the HFEA would
deal with up to 150 cases per year was not part of the wider discussions. When asked a
question13 about the possibility of 150 cases coming forward per year, the Chair of the
HFEA echoed the claim that only around 10 applications were expected per year and
that the Authority had the resources to cope with that number. No acknowledgement
was made that the higher figure might be possible. It is a moot point as to what impact
the higher numbers had on the views of Parliamentarians, but clearly the higher figures
could be deployed to make the case that PNT/MST interventions are much needed,
while the lower number was deployed to reassure all parties that regulatory oversight
could and would be provided. Whatever the baseline figures, the work for the HFEA
may be increased given the recent recommendation from the Newcastle Group that
PNT should only be used in conjunction with embryo screening (Hyslop et al. 2016).
The variations in calculations of the numbers of cases, plus the failure to systematic-
ally consider the possible implications of the higher numbers for effective regulatory
oversight, erodes confidence in Walport’s claim, cited earlier, that the UK are ‘very good
at the regulation and… very good at the public discussion’.
(ix)The egg providers.
As we have detailed elsewhere (Haimes and Taylor 2015) the discussion of the egg
providers (for both research and treatment), and the terminology used to describe them
in the debates, was problematic. Little, if anything, was said about the role and contri-
butions made by these women. Indeed it appears that their role was deliberately mini-
mised: for example, the NCoB argued they should not ‘be given the same status in all
aspects of regulation as a reproductive egg or embryo donor’ (2012, para 5.3) and the
HFEA ‘Advice to Government’ reduced their status to that of mere ‘tissue donors’
(2013, para 1.13). The commitment of time, energy and generosity required from the
egg providers and the invasiveness of the procedure through which the eggs are pro-
duced and collected for use in research or treatment were all but ignored. (For further
discussion see Baylis 2013, Haimes 2013, Haimes and Taylor 2013).
This is surprising given the very simple fact that without the egg providers no re-
search, let alone PNT/MST clinical interventions, would have been possible. How-
ever, this airbrushing14 (Haimes and Taylor 2015) which renders them invisible can
be more clearly understood in light of other aspects of the UK debates, such as the
playing down of the genetic contribution that egg providers will make to any off-
spring conceived (see section vi above), the unwillingness to consider other means
of conception (see section i above) and the valorisation of the genetic connection
between the intending parents and the person conceived (see section ii above).
These reflect the longstanding uneasiness amongst clinicians and regulators about
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the role of third party conceptions (Haimes 1998, Turkmendag 2016), of which this
is the latest manifestation. It is as though the egg provider is ‘the other woman’
whose necessary role in the process is all the more embarrassing precisely because
it is necessary. While careful consideration does need to be given to the nature of
the longer-term relationship between egg providers and those conceived, this is not
achieved by disguising the role of egg providers but rather by acknowledging, and
indeed celebrating, their vital contributions to these developments (Haimes and
Taylor 2015).
(x)Rapid legislation:
A recurring theme throughout the UK discussions was that time was of the essence
in changing the law to permit the clinical use of PNT/MST. For example in the House
of Lords debate on 24/02/15,
Viscount Ridley (Con): … Finally, is it rushed? Far from being hurried, it has been
under development for more than 30 years, under debate for 15 and under scrutiny
for five. There is nothing slippery about this slope. There has been no rush. Now,
however, that we have reached this stage there jolly well should be some reasonable
haste on behalf of the women whose reproductive life is running out and who
desperately want their own child, people such as Claire Wright, who is now 40 and
who had to watch her son Jacob lose his smile on the way to a cruel death. Yes,
there is understandable urgency. We would have to have very good reasons to argue
that the ethical thing to do is to prolong her suffering and that of others like her. I
cannot see those reasons (Hansard 2015b: Col 1588).
This need for rapid legislation was challenged on the grounds that the safety issues
had not yet been resolved. Bruce, speaking in the House of Commons in September
2014, noted,
Bruce (Congleton) (Con): … Sir John Tooke, president of the Academy of Medical
Sciences has said: “Introducing regulations now will ensure that there is no avoidable
delay in these treatments reaching affected families once there is sufficient evidence of
safety and efficacy.” In other words, Parliament should vote blind and sign off
legislation permitting these procedures before the recommended experiments—some
of them critical, regarding safety—have been completed (Hansard 2014: Col 94).
While an acknowledged opponent of embryo research in general, Bruce here is ex-
pressing concerns that Parliament would (and did) vote on the legislation with incom-
plete understanding of the safety of PNT/MST and therefore with an incomplete
understanding of the possible long-term consequences for the affected women and any
offspring they may have through using these techniques.
Support for the view that there were grounds for delaying legislation comes from pri-
mate research in the USA. This was given little exposure during the wider UK debates
even though the HFEA safety panel (HFEA 2014) did note that Mitalipov’s group in
Oregon had four five-year old male Macaques, conceived using MST techniques:
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The group is seeking to establish the fertility status of the Macaques by entering
them into a breeding programme and more focussed studies looking at physiological
impact will be conducted. There remains one female Macaque who is 2–3 years
old… that has not yet reached sexual maturity (HFEA, 2014, paragraph 3.3.3).
This means that it would only have been two to three years before the health of any
offspring from the female Macaque could be established and therefore any long term
negative consequences detected. Some Parliamentarians, such as Bruce above, clearly
thought that waiting until these (and other) safety experiments had been completed
would have been prudent. Therefore, within the terms of existing and imminent
knowledge within the field, it could be argued that there was an over-hasty move
to legislation.
We can see in the contrast between Ridley and Bruce a tension, also unexplored in
the wider discussions, between the very real needs of individuals (named individuals in
particular) and consideration of the wider, public health, benefits, risks and costs to
society as a whole of the introduction of these techniques. As Dawson argues, a focus
on individuals reflects trends elsewhere, but at a cost:
Much contemporary medical ethics focuses on the values considered to be crucial in
protecting the individual. Such values are important, but other values, more visible
in public health practice and related to societies, populations and communities, are
just as important (Dawson, 2015, p109).
Similarly, Petrini and Ricciardi (2015) describe the need for ‘the balancing of in-
dividual rights and collective interests, which are often in conflict’ (2015, 270). It
could be argued that legalising PNT/MST operates in an inverse manner to public
health measures such as vaccination, which requires that parents take a risk with
their child for the benefit of the population (Wood-Harper 2005) since the former
entails taking a risk with the future of the population, through the unknown and
irreversible consequences of modifying the germline, in favour of the immediate,
hoped-for benefits to individual families.15
Discussion
In summary, we have identified ten areas in which the UK discussions of PNT/MST
initiatives would have benefitted from greater clarity, depth and nuance; in each area
we have highlighted information and knowledge that could have been more prominent
and contributed to a more fully rounded debate. Through this analysis we have sharp-
ened awareness of the wider social implications of this cutting-edge science, by contex-
tualising these developments and drawing more centrally into consideration questions
concerning, amongst other things: the reproductive choices available; the kinship rela-
tionships created; the relationship between safety and ethics; the characterisations of
the assumed beneficiaries; the ambitions and limitations of the proposed interventions,
and the challenges for regulatory capacity. These contributions are important since,
while the UK legislation has already been changed, details of implementation, regula-
tion and practice have not yet settled into place; alerting the field to the need to con-
sider these areas, and the challenges they represent, is a timely and useful task. While
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some of these topics constitute a critique of the UK debates, others support the claims
of those eager to translate the science into clinical applications as fully as possible; the
point of this analysis is not simply to pick holes in existing debates but to assist in en-
suring that the full range of deliberations is as strong and clear as possible. Together,
the examination of these areas enhances our understandings of the contributions that
mitochondrial interventions can make and enhances our understandings of how this
new science can best be developed to benefit those who want and need it most; it also
assists the achievement of a more measured evaluation of the wider social and ethical
impacts of these developments.
This more moderate, and modest, assessment is necessary since the existing UK
debates on mitochondrial interventions, including their influence on the legislative
process, raise questions about the governance of this, and associated areas of bio-
technology, in at least three related areas. (i) The protection of women, offspring
and patients. The protection of research participants and of patients is one of the
key roles of any governance system in biomedical sciences. In research involving
assisted reproduction, the protection of any persons born and that of the providers
of gametes or embryos must also be considered. However, in the case of the clin-
ical applications of PNT/MST we have demonstrated that the regulations passed in
Parliament, and which will be implemented by the HFEA, were influenced by, and
so repeated, the weaknesses prevalent in the wider discussions. For example, the
‘strategy of persuasion’ (Haimes 2014) adopted by proponents of the techniques
acted to reduce the egg provider to just a ‘tissue donor’ (HFEA 2013). This results
in her being considered in law in a more instrumental way than other women who
provide eggs for treatment in other circumstances, insofar as she is seen merely in
terms of her provision of healthy mitochondria rather than in terms of her own
agency in acting in such altruistic ways or for her wider contributions to the field
as a whole (see section (ix) above and Haimes and Taylor 2015). Similarly, the pro-
tection of any people born as a result of PNT/MST should also require that the
techniques used in their conception be as safe as possible, in accordance with
agreed clinical standards (see section (iii) above). However, in confidently dismiss-
ing opponents’ questioning of safety as being rooted in questions of values, some
proponents of the interventions (Jack 2016) closed down the possibility of open
discussion that is a requirement of good systems of governance. This raises ques-
tions about the effective protection of the offspring and the women who bear them
(Crouch 2016). There is no doubt that the clinician-scientists involved in develop-
ing PNT/MST have the best interests of their patients at heart and are concerned
for the safety and wellbeing of all involved. However, the manner in which safety
concerns, raised in good faith, were dismissed by some supporters of PNT/MST
interventions is not what might be expected in a high quality discussion.
(ii) The legitimacy of focussing on short-term benefit. Given the concerns over
safety and the other issues raised above, there are, as we have seen, valid questions over
the legitimacy of the law being changed when, and how, it was. The case of PNT/MST
shares similarities with earlier debates on biotechnology studied by Brown and Benyon-
Jones (2012). In their work on UK policymaking and regulation of xenotransplantation
and human-animal hybrid embryos these authors identified a process which they
termed ‘reflex regulation’, defined as,
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…a sustained and default assemblage of conditioned and habitual regulatory
behaviours and impulses that adversely limit potentially more critical and reflexive
regulatory deliberation (Brown and Benyon-Jones 2012, 224).
They concluded that,
…reflex regulation is characterised by a focus on promissory risk and an emphasis
on avoiding the loss of opportunity over that of avoiding other hazards and dangers.
… This resonates closely with what we have called the ‘technocratic reflex’, i.e. policy
culture’s enduring deference to scientific stakeholders’ definitions of risk in spite of a
widely purported policy ‘turn’ towards greater inclusivity in deliberation concerning
technoscientific futures (2012, 237).
In the case of PNT/MST we have seen both the emphasis on pressing ahead with le-
gislation to enable the clinician-scientists to offer treatment quickly to affected women,
accompanied by the effective (even if unintentional) silencing of criticisms of the sci-
ence. We have highlighted the absence of informed discussion of the risks to wider so-
ciety and the focus instead on the risks to individuals from not being offered treatment,
despite the supposedly ‘open’ approach to policymaking and governance espoused by
Government (HM Government 2013).
One means of achieving the better regulation envisaged by Brown and Benyon-Jones
could result from the adoption of the principle of ‘Responsible Research and
Innovation’ (RRI) (Stilgoe et al. 2013). This approach to the conduct of science has re-
cently been gaining importance, particularly at European level (EU 2016). Stilgoe et al.
identify how, despite recent approaches that include consultation or engagement with a
range of stakeholders, in a bid to identify wider concerns about the purposes of and
motivation for research, current governance arrangements for science are still focussed
on the narrower, formalised means of risk assessment (2013, 1569).
In an effort to develop a framework for ‘responsible research’ Stilgoe et al. avoid the
approach taken by others (e.g. von Schomberg 2011) who see RRI as a means of pursu-
ing particular values and desired outcomes, and instead focus on the processes of
governance that encompass ‘the distinctive social and ethical stakes’ in technological
developments (quoted in Stilgoe et al. 2013, 1577). It is just this sort of focus on the
wider societal interests in PNT/MST that our ten areas add to the UK debates and any
subsequent regulation processes.
We can see that Government policymaking on PNT/MST prioritised the ‘promo-
tional narratives of near-term future benefits’ (Brown and Benyon-Jones, 2012, 237) in
which the views of some stakeholders, particularly the proponents of the science, were
privileged over others. Examples of this were provided by the lack of systematic consid-
eration of alternative ways women might have an unaffected child and also by the Chief
Medical Officer’s statement that,
[s]cientists have developed ground-breaking new procedures which could stop these
diseases being passed on, bringing hope to many families seeking to prevent their fu-
ture children inheriting them. It’s only right that we look to introduce this life-saving
treatment as soon as we can (Department of Health 2013).
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(iii) The risk to public trust. We have raised concerns about the protection of those
who may be involved in research and clinical applications of PNT/MST and about the
legitimacy of the rapid legislative process by which clinical applications have been en-
abled. Such concerns have implications for the trust that wider publics might or might
not have in biosciences. By pressing ahead without a more detailed and more nuanced
discussion that could have involved more diverse publics, more thoroughly, the propo-
nents of PNT/MST risk jeopardising the trust in medical scientists currently held by
those publics (Castell et al. 2014, Marris 2015). As Brown and Benyon-Jones showed,
the promise of areas such as human-animal hybrid embryos for research and medicine
has been left unfulfilled, as indeed is the case for much that was expected of human
embryonic stem cell research. Should the proposed clinical application of PNT/MST be
less than hoped for, or worse still, cause harm, then wider publics are even more likely
to come to distrust both the therapeutic promise of other new technologies and those
who make such promises.
One means of building or maintaining public trust in the biosciences is through the
design and implementation of good governance structures; however, as Harmon et al.
note, this is not straightforward:
The modern biosciences require governance frameworks that are capable of
simultaneously managing risk, coping with uncertainty, combating ambivalence, and
building trust, all the while encouraging the delivery of those instrumental outputs
that we value/demand (better health, new technologies, commercial reward). This
multi-dimensional task makes the design and delivery of good governance frame-
works … extremely difficult (Harmon et al. 2013, 31).
In Harmon et al’s view, which mirrors those of Stilgoe et al. (2013) and Brown and
Benyon-Jones (2012), approaches to the governance of bioscience have tended to be
inadequate. One reason for such inadequacy is that a key element of good governance
is an assessment of the risk, in the wider, socially-defined, understandings of that
term, posed by a particular technology or process. Harmon et al’s review of the work
in this field leads them to conclude that the scientific understanding of the risks of
biosciences are incomplete and ‘risk articulations are tentative and sound assessments
are not yet within our grasp’ (2013, 26). In such a situation, legislators face a dilemma:
should the law be used to prohibit certain technologies, or promote them, given that
risks are largely unknown? A precautionary approach may be taken, but Harmon et al.
consider this to be a contributing factor to the ambivalence around bioscience observed
in wider publics.
Many authors have suggested that biotechnology governance frameworks would
benefit by involving publics in their development, which, it is argued, would also lead
to increased trust in biosciences (e.g. Harmon et al. 2013, 27). Public consultations are
mechanisms frequently employed to involve publics in the legislative process; this was,
as we have shown, an approach taken in the legalisation of PNT/MST therapies. How-
ever, the timing of the HFEA consultation in 2012 (let alone its conduct) can be seen
as a concern, since, as Harmon et al. note, one-off, ‘snapshot’ consultations are inad-
equate for capturing the nuances of opinion about rapidly developing fields such as
PNT/MST; they recommend ongoing dialogues between publics and policymakers
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instead (2013,28). These authors see a positive role for public engagement when done
thoughtfully and robustly, providing policy-makers with ongoing evidence, assessment
of risks and understanding of values that could inform governance frameworks over
time. However, this was not aimed for, let alone achieved, in the case of PNT/MST.
Concluding comments
Other jurisdictions might appreciate the usefulness of a more fully rounded debate. As
Bredenoord and Hyun (2015) argue, when discussing whether the USA should follow
the UK’s lead in permitting MST/PNT, ‘The bold leap from bench to bedside needs suf-
ficient preclinical evidence and careful, long-term interdisciplinary research, including
more ethics research’ (2015, 976). They recommend that the USA should take a more
cautious path and argue, ‘A cautionary approach means that a wide variety of concerns
should be taken seriously – wider than safety and efficacy alone’; the need is to find a
balance between ‘taking appropriate precautions and not unnecessarily hampering
innovation’ (2015,976). The US National Academies of Science, Engineering and Medi-
cine report on mitochondrial disease (National Academies of Sciences, Engineering,
and Medicine 2016) describes these interventions as raising ‘a novel collection of
ethical, social and policy issues’ (2016, xiii). The starting point for their deliberations
was ‘parental motivation’ for using these techniques in light of ‘alternative approaches
to creating families’ and the ‘primary value’ to be considered when balancing risks and
benefits of further clinical investigations was ‘minimizing the risk of harm to the child
born as a result’ (2016, xv). They concluded that it is ethically permissible to conduct
clinical investigations of these interventions but with two major restrictions: that inves-
tigation should be limited to women at risk of transmitting a serious mitochondrial
disease and that only male embryos are transferred for gestation, ‘to avoid introducing
heritable genetic modification during initial clinical investigations’. (2016, xv). While
this second restriction raises its own ethical challenges in creating ‘experimental off-
spring’ (Taylor and Haimes 2012, NCoB 2012, 80), the USA is clearly taking more time
to reach a decision and appears unlikely to follow the same path as the UK.
As we have shown, many important areas were neglected in the UK debates and the
claims about the quality of those debates are over-stated. It is impossible to say what
the outcome of the debates would have been had these more nuanced discussions been
included. What we can suggest is that by leading the argument in the way that they
did, focussing on the emotive and profoundly distressing effects of mitochondrial dis-
ease on babies, children and their families, and by failing to address a range of other is-
sues in detail, the proponents of the technology leave themselves open to challenge in
the future should the techniques fail to have as powerful an impact on mitochondrial
diseases as some parties to the debates clearly expect them to have, or prove to be un-
safe, or lead to other (perhaps more commercial and exploitative16) uses being
approved.
The analysis presented here provokes the question of where the UK stands on the
global stage in relation to mitochondrial interventions. Clearly the scientific endeavour
in the UK is at the cutting edge of progress in this field. However, given that the UK
legislation is the first example of the permissibility of genetic modification of human
beings, and given the more cautious approach recommended for, and being taken by,
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the USA and Australia (de Lacey 2016), it could be argued that the UK is precariously
out on a regulatory limb,17 until the many aspects discussed in this article are
more clearly understood.
Endnotes
1As we have explained elsewhere, the terms ‘mitochondrial donation’ and ‘mitochondria
donor’ are ‘misleading as they imply a direction of travel for the mitochondria that is in
fact the opposite of what will actually occur. In the therapeutic application of PNT, an egg
from the intending mother will be fertilised using sperm from the intending father. At the
same time, an egg provided by a volunteer will be fertilised by the intending father’s sperm
and that fertilised egg will be enucleated. The intending parents’ nuclear DNA, in the
form of two pronuclei from their own fertilised egg, will then be transplanted into the
enucleated egg which then acts as a ‘host’ to the transplanted nuclear DNA. MST will
similarly involve the transfer of the intending mother’s nuclear DNA into an enucleated
egg from the egg provider; that egg will then be fertilised by the intending father’s sperm.
In other words, the egg provider’s mitochondria, whether in research or treatment con-
texts, are not moved anywhere. Therefore, rather than phrases such as ‘mitochondria do-
nation/transfer/replacement’, a more accurate term would be ‘nuclear DNA hosting’, for
both PNT and MST.’ (Haimes and Taylor 2015, 364-5).
2Throughout this paper we discuss mitochondria as related to human life processes
and health, though of course mitochondria are present in the cells of all multicellular
organisms.
3We use this term to emphasise that those leading the research on PNT/MST
also tend to have clinical roles in diagnosing and caring for people affected by
mitochondrial disease.
4The authors are employed at the same university as that to which the clinician-
scientists engaged in mitochondrial research and the recruitment of egg providers are
affiliated, and our study was funded by the same organisation (Wellcome Trust) that
funds the scientific research. However, our study was independent. We were assisted by
a Project Advisory Group comprised of senior academics from other universities to
ensure analytical objectivity.
5We do not claim to have conducted a full blown ‘media analysis’ as our aim is to
identify themes cutting across the different contributions to the UK debates rather than
to analyse how one particular type of contribution (the ‘mass media’) shaped the overall
debates. Newspaper and other media articles were identified via the systematic collation
of all reporting (favourable or otherwise) of the work on mitochondrial disease in-
terventions by Newcastle University-based clinician-scientists carried out by the
University’s Press Office between May 2010 and September 2016, augmented by
our own online searches.
6Of course from the egg provider’s point of view all such measures entail giving a
whole egg; however the distinction we draw here is between ‘traditional’ egg provision
that contributes 50% of the genetic material to any resultant offspring, the donated egg
completely replacing the intending mother’s egg, compared to egg provision in PNT/
MST which will result in a smaller amount of genetic material being contributed and
combined with both the intending parents’ DNA.
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7While it is always difficult to prove the absence of any feature, further evidence of
the lack of consideration of alternative routes to reproduction can be found in utter-
ances such as that from the lead scientist, Professor Turnbull, on greeting the news in
December 2016 that approval might be given for the go ahead of clinical applications
for PNT/MST: ‘This gives women who have mitochondrial DNA mutations
reproductive choice, and I am delighted for them.'. The implication here is that they
did not have any choices prior to this. See also section (ii) ‘Valorising ‘genetic connections”
in this article.
8The references given in the text ‘[6-8]’ are to scientific papers describing the experi-
mental methods; no evidence is offered for the claim that the need for ‘this technique
… is well established’.
9It is of course possible to refer to ‘adult children’ in everyday speech but that quali-
fying adjective was also absent in these discussions, which further underlines the view
that the prevailing tendency was to see the person conceived only in their infant status.
10It is not clear precisely how these various parties were calculating their figures,
given the variations between 0.1% and 0.01%, but they were all very clear that the
figures were very small.
11The ONS report that there are 52,798,300 adults in UK (ONS, http://www.ons.gov.
uk/ons/rel/pop-estimate/population-estimates-for-uk–england-and-wales–scotland-and-
northern-ireland/2013/sty-population-estimates.html). Using the figure given by Craven
et al. of 1 in 10,000 affected individuals implies that around 5280 adults in the UK are
affected. As mitochondrial diseases affect both sexes equally, this figure is in line with the
estimate of 2473 affected women reported by Gorman et al. (2015).
12The HFEA report that ‘Around 1 in 6500 children [are] thought to be born with a
serious mitochondrial disorder due to faults in mitochondrial DNA’ (HFEA 2014). The
Office of National Statistics report that in 2012 there were 729,674 live births in England
and Wales. This suggests an incidence of 729,674/6500 = 112 affected children born per
year. However, Sanderson et al. (2006) report the incidence of mitochondrial disorders as
1 in 4929. Thus, England and Wales would expect to see 729,674/4929 = 148 new cases of
mitochondrial diseases in children per year.
13The question was asked by one of the authors, KT, at the same December 2015
conference in which Walport made the remarks quoted earlier.
14The airbrushing of the egg providers’ role also poses threats to their own health
since no consideration was given in the UK debates to the health screening of potential
providers nor to the handling of any incidental findings or adverse information relevant
to the providers’ health arising from that screening (Applebaum et al. 2014; Haimes
and Taylor 2015).
15Tangential to the concerns about over-rapid legislation were concerns expressed
about ‘slippery slopes’. Opponents of PNT/MST often raised concerns that the legalisa-
tion of these techniques would lead to other forms of genetic modification of embryos
(see for example McKie 2014). These claims were contested by the proponents of
PNT/MST (see for example McKie 2014, Lily Foundation 2015) who argued that alter-
ing nuclear DNA would remain illegal and that PNT/MST were solely for the purpose
of removing these mitochondrial diseases from the germline of the offspring of affected
women. However, soon after the House of Commons vote, the afore-mentioned re-
searcher, Mitalipov, was quoted as saying that he hoped to be able to use the MST
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technique to enable older infertile women have genetically related children (Farmer
2015). Similarly, Walport’s claims, cited earlier, that approval of ‘mitochondrial dona-
tion’ provides a blueprint for future decisions on modifying the genome, is further evi-
dence for those who fear that the slope beckons.
16See the discussion of Mitalipov in footnote 15 above.
17With reference to Walport’s claim that the UK legislation provides a blue print for
future decisions on modifying the genome, it is sobering to note that in the world of
architecture, blueprints are not the finished product that popular usage of the term im-
plies. The technology to make blueprints always resulted in the finished product being
slightly smaller than the original drawing as the medium on which the blueprint was
made shrank as it dried (Liebing, 1999). Blueprints carried a warning (as do their modern,
digital, equivalents) reminding architects and engineers not to take measurements directly
from them, but to look elsewhere for the necessary details to construct a stable, safe and
long-lasting structure.
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